Article Contents ::

Details About Generic Salt ::  Valacycl

Main Medicine Class:: Anti-infective, Antiviral   

(val-lay-SIGH-kloe-vihr HIGH-droe-KLOR-ide)
Valtrex
Tablets: 500 mg
Tablets: 1 g
Class: Anti-infective, Antiviral

 

 Action Converted to acyclovir, which then inhibits viral DNA replication by interfering with viral DNA polymerase.

 

 Indications Treatment of herpes zoster (shingles); treatment or suppression of genital herpes; treatment of herpes labialis (cold sores).

 

 Contraindications Hypersensitivity or intolerance to valacyclovir, acyclovir, or any component of the formulation.

 

 Route/Dosage

Herpes Zoster

Adults: PO 1 g tid for 7 days (initiate therapy within 48 hr of onset of rash).

Genital Herpes

Adults: PO Initial episodes: 1 g bid for 10 days (initiate therapy within 48 to 72 hr of onset of signs and symptoms). Recurrent episodes: 500 mg bid for 3 days (initiate therapy within 24 hr of onset of signs or symptoms). Suppressive therapy: 1 g once daily. If history of recurrence up to 9 recurrences/yr, 500 mg/day may be administered.

Herpes Labialis

Adults: PO 2 g bid for 1 day approximately 12 hr apart, initiated at earliest symptoms of cold sore (eg, tingling, burning, itching).

 

 Interactions

Cimetidine, probenecid:

Increased acyclovir serum concentrations.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

CNS: Headache; dizziness. GI: Nausea; vomiting; diarrhea; constipation; abdominal pain; anorexia. OTHER: Asthenia.

 

 Precautions

Pregnancy: Category B. Lactation: Undetermined (acyclovir is excreted in breast milk). CHILDREN: Safety and efficacy not established. Elderly: Dosage reduction may be necessary, depending on underlying renal status. Renal function impairment: Dosage reduction may be necessary; exercise caution when giving valacyclovir to patients with renal impairment or those receiving potentially nephrotoxic drugs. Immunocompromised: Valacyclovir is not indicated for use in immunocompromised patients.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • May be taken without regard to meals.
  • Store at room temperature.

 

 Assessment/Interventions

  • Obtain patient history.
  • Assess for history of present herpes zoster illness and time of rash onset. Start treatment up to 72 hr after rash onset.
  • Monitor for effectiveness of treatment: Crusting and disappearance of hepatic zoster lesions; pain relief.
  • Assess for history of present genital herpes illness and time of onset of signs and symptoms. Initiate treatment within 48 to 72 hr of onset of signs and symptoms.
  • Monitor for effectiveness of treatment (ie, improvement in signs and symptoms).
  • Assess for history of present, recurrent genital herpes illness and time of onset of signs and symptoms. Initate treatment within 24 hr of onset of signs and symptoms.
  • Monitor for effectiveness of treatment (ie, improvement in signs and symptoms).
OVERDOSAGE: SIGNS & SYMPTOMS
  Acute renal failure, anuria

 

 Patient/Family Education

Herpes Zoster

  • Advise patient to initiate treatment as soon as possible after diagnosis of herpes zoster and up to 72 hr after onset of zoster rash.
  • Instruct patient to take medication exactly as prescribed.
  • Instruct patient not to alter dose or discontinue medication without consulting health care provider.
  • Instruct patient not to take any other medications, including OTC medications, without checking with health care provider first.
  • Instruct patient to notify health care provider if there is no reduction in severity of lesions within 7 days.
  • Inform patient to report any serious side effects to health care provider, including: syncope, dizziness, nausea, vomiting, diarrhea, headache, abdominal pain, anorexia.

Genital Herpes

  • Advise patient to avoid sexual intercourse while genital herpes lesions are present.
  • Tell patient that valacyclovir is a treatment not a cure.
  • Advise patient to initiate therapy at first sign of symptoms of an episode.
  • Instruct patient to notify health care provider if there is no reduction in severity of signs and symptoms.

 

Drugs Class ::

(val-lay-SIGH-kloe-vihr HIGH-droe-KLOR-ide)
Valtrex
Tablets: 500 mg
Tablets: 1 g
Class: Anti-infective, Antiviral

 

 Action Converted to acyclovir, which then inhibits viral DNA replication by interfering with viral DNA polymerase.

 

 Indications Treatment of herpes zoster (shingles); treatment or suppression of genital herpes; treatment of herpes labialis (cold sores).

 

 Contraindications Hypersensitivity or intolerance to valacyclovir, acyclovir, or any component of the formulation.

 

 Route/Dosage

Herpes Zoster

Adults: PO 1 g tid for 7 days (initiate therapy within 48 hr of onset of rash).

Genital Herpes

Adults: PO Initial episodes: 1 g bid for 10 days (initiate therapy within 48 to 72 hr of onset of signs and symptoms). Recurrent episodes: 500 mg bid for 3 days (initiate therapy within 24 hr of onset of signs or symptoms). Suppressive therapy: 1 g once daily. If history of recurrence up to 9 recurrences/yr, 500 mg/day may be administered.

Herpes Labialis

Adults: PO 2 g bid for 1 day approximately 12 hr apart, initiated at earliest symptoms of cold sore (eg, tingling, burning, itching).

 

 Interactions

Cimetidine, probenecid:

Increased acyclovir serum concentrations.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

CNS: Headache; dizziness. GI: Nausea; vomiting; diarrhea; constipation; abdominal pain; anorexia. OTHER: Asthenia.

 

 Precautions

Pregnancy: Category B. Lactation: Undetermined (acyclovir is excreted in breast milk). CHILDREN: Safety and efficacy not established. Elderly: Dosage reduction may be necessary, depending on underlying renal status. Renal function impairment: Dosage reduction may be necessary; exercise caution when giving valacyclovir to patients with renal impairment or those receiving potentially nephrotoxic drugs. Immunocompromised: Valacyclovir is not indicated for use in immunocompromised patients.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • May be taken without regard to meals.
  • Store at room temperature.

 

 Assessment/Interventions

  • Obtain patient history.
  • Assess for history of present herpes zoster illness and time of rash onset. Start treatment up to 72 hr after rash onset.
  • Monitor for effectiveness of treatment: Crusting and disappearance of hepatic zoster lesions; pain relief.
  • Assess for history of present genital herpes illness and time of onset of signs and symptoms. Initiate treatment within 48 to 72 hr of onset of signs and symptoms.
  • Monitor for effectiveness of treatment (ie, improvement in signs and symptoms).
  • Assess for history of present, recurrent genital herpes illness and time of onset of signs and symptoms. Initate treatment within 24 hr of onset of signs and symptoms.
  • Monitor for effectiveness of treatment (ie, improvement in signs and symptoms).
OVERDOSAGE: SIGNS & SYMPTOMS
  Acute renal failure, anuria

 

 Patient/Family Education

Herpes Zoster

  • Advise patient to initiate treatment as soon as possible after diagnosis of herpes zoster and up to 72 hr after onset of zoster rash.
  • Instruct patient to take medication exactly as prescribed.
  • Instruct patient not to alter dose or discontinue medication without consulting health care provider.
  • Instruct patient not to take any other medications, including OTC medications, without checking with health care provider first.
  • Instruct patient to notify health care provider if there is no reduction in severity of lesions within 7 days.
  • Inform patient to report any serious side effects to health care provider, including: syncope, dizziness, nausea, vomiting, diarrhea, headache, abdominal pain, anorexia.

Genital Herpes

  • Advise patient to avoid sexual intercourse while genital herpes lesions are present.
  • Tell patient that valacyclovir is a treatment not a cure.
  • Advise patient to initiate therapy at first sign of symptoms of an episode.
  • Instruct patient to notify health care provider if there is no reduction in severity of signs and symptoms.

Indications for Drugs ::

(val-lay-SIGH-kloe-vihr HIGH-droe-KLOR-ide)
Valtrex
Tablets: 500 mg
Tablets: 1 g
Class: Anti-infective, Antiviral

 

 Action Converted to acyclovir, which then inhibits viral DNA replication by interfering with viral DNA polymerase.

 

 Indications Treatment of herpes zoster (shingles); treatment or suppression of genital herpes; treatment of herpes labialis (cold sores).

 

 Contraindications Hypersensitivity or intolerance to valacyclovir, acyclovir, or any component of the formulation.

 

 Route/Dosage

Herpes Zoster

Adults: PO 1 g tid for 7 days (initiate therapy within 48 hr of onset of rash).

Genital Herpes

Adults: PO Initial episodes: 1 g bid for 10 days (initiate therapy within 48 to 72 hr of onset of signs and symptoms). Recurrent episodes: 500 mg bid for 3 days (initiate therapy within 24 hr of onset of signs or symptoms). Suppressive therapy: 1 g once daily. If history of recurrence up to 9 recurrences/yr, 500 mg/day may be administered.

Herpes Labialis

Adults: PO 2 g bid for 1 day approximately 12 hr apart, initiated at earliest symptoms of cold sore (eg, tingling, burning, itching).

 

 Interactions

Cimetidine, probenecid:

Increased acyclovir serum concentrations.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

CNS: Headache; dizziness. GI: Nausea; vomiting; diarrhea; constipation; abdominal pain; anorexia. OTHER: Asthenia.

 

 Precautions

Pregnancy: Category B. Lactation: Undetermined (acyclovir is excreted in breast milk). CHILDREN: Safety and efficacy not established. Elderly: Dosage reduction may be necessary, depending on underlying renal status. Renal function impairment: Dosage reduction may be necessary; exercise caution when giving valacyclovir to patients with renal impairment or those receiving potentially nephrotoxic drugs. Immunocompromised: Valacyclovir is not indicated for use in immunocompromised patients.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • May be taken without regard to meals.
  • Store at room temperature.

 

 Assessment/Interventions

  • Obtain patient history.
  • Assess for history of present herpes zoster illness and time of rash onset. Start treatment up to 72 hr after rash onset.
  • Monitor for effectiveness of treatment: Crusting and disappearance of hepatic zoster lesions; pain relief.
  • Assess for history of present genital herpes illness and time of onset of signs and symptoms. Initiate treatment within 48 to 72 hr of onset of signs and symptoms.
  • Monitor for effectiveness of treatment (ie, improvement in signs and symptoms).
  • Assess for history of present, recurrent genital herpes illness and time of onset of signs and symptoms. Initate treatment within 24 hr of onset of signs and symptoms.
  • Monitor for effectiveness of treatment (ie, improvement in signs and symptoms).
OVERDOSAGE: SIGNS & SYMPTOMS
  Acute renal failure, anuria

 

 Patient/Family Education

Herpes Zoster

  • Advise patient to initiate treatment as soon as possible after diagnosis of herpes zoster and up to 72 hr after onset of zoster rash.
  • Instruct patient to take medication exactly as prescribed.
  • Instruct patient not to alter dose or discontinue medication without consulting health care provider.
  • Instruct patient not to take any other medications, including OTC medications, without checking with health care provider first.
  • Instruct patient to notify health care provider if there is no reduction in severity of lesions within 7 days.
  • Inform patient to report any serious side effects to health care provider, including: syncope, dizziness, nausea, vomiting, diarrhea, headache, abdominal pain, anorexia.

Genital Herpes

  • Advise patient to avoid sexual intercourse while genital herpes lesions are present.
  • Tell patient that valacyclovir is a treatment not a cure.
  • Advise patient to initiate therapy at first sign of symptoms of an episode.
  • Instruct patient to notify health care provider if there is no reduction in severity of signs and symptoms.

Drug Dose ::

(val-lay-SIGH-kloe-vihr HIGH-droe-KLOR-ide)
Valtrex
Tablets: 500 mg
Tablets: 1 g
Class: Anti-infective, Antiviral

 

 Action Converted to acyclovir, which then inhibits viral DNA replication by interfering with viral DNA polymerase.

 

 Indications Treatment of herpes zoster (shingles); treatment or suppression of genital herpes; treatment of herpes labialis (cold sores).

 

 Contraindications Hypersensitivity or intolerance to valacyclovir, acyclovir, or any component of the formulation.

 

 Route/Dosage

Herpes Zoster

Adults: PO 1 g tid for 7 days (initiate therapy within 48 hr of onset of rash).

Genital Herpes

Adults: PO Initial episodes: 1 g bid for 10 days (initiate therapy within 48 to 72 hr of onset of signs and symptoms). Recurrent episodes: 500 mg bid for 3 days (initiate therapy within 24 hr of onset of signs or symptoms). Suppressive therapy: 1 g once daily. If history of recurrence up to 9 recurrences/yr, 500 mg/day may be administered.

Herpes Labialis

Adults: PO 2 g bid for 1 day approximately 12 hr apart, initiated at earliest symptoms of cold sore (eg, tingling, burning, itching).

 

 Interactions

Cimetidine, probenecid:

Increased acyclovir serum concentrations.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

CNS: Headache; dizziness. GI: Nausea; vomiting; diarrhea; constipation; abdominal pain; anorexia. OTHER: Asthenia.

 

 Precautions

Pregnancy: Category B. Lactation: Undetermined (acyclovir is excreted in breast milk). CHILDREN: Safety and efficacy not established. Elderly: Dosage reduction may be necessary, depending on underlying renal status. Renal function impairment: Dosage reduction may be necessary; exercise caution when giving valacyclovir to patients with renal impairment or those receiving potentially nephrotoxic drugs. Immunocompromised: Valacyclovir is not indicated for use in immunocompromised patients.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • May be taken without regard to meals.
  • Store at room temperature.

 

 Assessment/Interventions

  • Obtain patient history.
  • Assess for history of present herpes zoster illness and time of rash onset. Start treatment up to 72 hr after rash onset.
  • Monitor for effectiveness of treatment: Crusting and disappearance of hepatic zoster lesions; pain relief.
  • Assess for history of present genital herpes illness and time of onset of signs and symptoms. Initiate treatment within 48 to 72 hr of onset of signs and symptoms.
  • Monitor for effectiveness of treatment (ie, improvement in signs and symptoms).
  • Assess for history of present, recurrent genital herpes illness and time of onset of signs and symptoms. Initate treatment within 24 hr of onset of signs and symptoms.
  • Monitor for effectiveness of treatment (ie, improvement in signs and symptoms).
OVERDOSAGE: SIGNS & SYMPTOMS
  Acute renal failure, anuria

 

 Patient/Family Education

Herpes Zoster

  • Advise patient to initiate treatment as soon as possible after diagnosis of herpes zoster and up to 72 hr after onset of zoster rash.
  • Instruct patient to take medication exactly as prescribed.
  • Instruct patient not to alter dose or discontinue medication without consulting health care provider.
  • Instruct patient not to take any other medications, including OTC medications, without checking with health care provider first.
  • Instruct patient to notify health care provider if there is no reduction in severity of lesions within 7 days.
  • Inform patient to report any serious side effects to health care provider, including: syncope, dizziness, nausea, vomiting, diarrhea, headache, abdominal pain, anorexia.

Genital Herpes

  • Advise patient to avoid sexual intercourse while genital herpes lesions are present.
  • Tell patient that valacyclovir is a treatment not a cure.
  • Advise patient to initiate therapy at first sign of symptoms of an episode.
  • Instruct patient to notify health care provider if there is no reduction in severity of signs and symptoms.

Contraindication ::

(val-lay-SIGH-kloe-vihr HIGH-droe-KLOR-ide)
Valtrex
Tablets: 500 mg
Tablets: 1 g
Class: Anti-infective, Antiviral

 

 Action Converted to acyclovir, which then inhibits viral DNA replication by interfering with viral DNA polymerase.

 

 Indications Treatment of herpes zoster (shingles); treatment or suppression of genital herpes; treatment of herpes labialis (cold sores).

 

 Contraindications Hypersensitivity or intolerance to valacyclovir, acyclovir, or any component of the formulation.

 

 Route/Dosage

Herpes Zoster

Adults: PO 1 g tid for 7 days (initiate therapy within 48 hr of onset of rash).

Genital Herpes

Adults: PO Initial episodes: 1 g bid for 10 days (initiate therapy within 48 to 72 hr of onset of signs and symptoms). Recurrent episodes: 500 mg bid for 3 days (initiate therapy within 24 hr of onset of signs or symptoms). Suppressive therapy: 1 g once daily. If history of recurrence up to 9 recurrences/yr, 500 mg/day may be administered.

Herpes Labialis

Adults: PO 2 g bid for 1 day approximately 12 hr apart, initiated at earliest symptoms of cold sore (eg, tingling, burning, itching).

 

 Interactions

Cimetidine, probenecid:

Increased acyclovir serum concentrations.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

CNS: Headache; dizziness. GI: Nausea; vomiting; diarrhea; constipation; abdominal pain; anorexia. OTHER: Asthenia.

 

 Precautions

Pregnancy: Category B. Lactation: Undetermined (acyclovir is excreted in breast milk). CHILDREN: Safety and efficacy not established. Elderly: Dosage reduction may be necessary, depending on underlying renal status. Renal function impairment: Dosage reduction may be necessary; exercise caution when giving valacyclovir to patients with renal impairment or those receiving potentially nephrotoxic drugs. Immunocompromised: Valacyclovir is not indicated for use in immunocompromised patients.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • May be taken without regard to meals.
  • Store at room temperature.

 

 Assessment/Interventions

  • Obtain patient history.
  • Assess for history of present herpes zoster illness and time of rash onset. Start treatment up to 72 hr after rash onset.
  • Monitor for effectiveness of treatment: Crusting and disappearance of hepatic zoster lesions; pain relief.
  • Assess for history of present genital herpes illness and time of onset of signs and symptoms. Initiate treatment within 48 to 72 hr of onset of signs and symptoms.
  • Monitor for effectiveness of treatment (ie, improvement in signs and symptoms).
  • Assess for history of present, recurrent genital herpes illness and time of onset of signs and symptoms. Initate treatment within 24 hr of onset of signs and symptoms.
  • Monitor for effectiveness of treatment (ie, improvement in signs and symptoms).
OVERDOSAGE: SIGNS & SYMPTOMS
  Acute renal failure, anuria

 

 Patient/Family Education

Herpes Zoster

  • Advise patient to initiate treatment as soon as possible after diagnosis of herpes zoster and up to 72 hr after onset of zoster rash.
  • Instruct patient to take medication exactly as prescribed.
  • Instruct patient not to alter dose or discontinue medication without consulting health care provider.
  • Instruct patient not to take any other medications, including OTC medications, without checking with health care provider first.
  • Instruct patient to notify health care provider if there is no reduction in severity of lesions within 7 days.
  • Inform patient to report any serious side effects to health care provider, including: syncope, dizziness, nausea, vomiting, diarrhea, headache, abdominal pain, anorexia.

Genital Herpes

  • Advise patient to avoid sexual intercourse while genital herpes lesions are present.
  • Tell patient that valacyclovir is a treatment not a cure.
  • Advise patient to initiate therapy at first sign of symptoms of an episode.
  • Instruct patient to notify health care provider if there is no reduction in severity of signs and symptoms.

Drug Precautions ::

(val-lay-SIGH-kloe-vihr HIGH-droe-KLOR-ide)
Valtrex
Tablets: 500 mg
Tablets: 1 g
Class: Anti-infective, Antiviral

 

 Action Converted to acyclovir, which then inhibits viral DNA replication by interfering with viral DNA polymerase.

 

 Indications Treatment of herpes zoster (shingles); treatment or suppression of genital herpes; treatment of herpes labialis (cold sores).

 

 Contraindications Hypersensitivity or intolerance to valacyclovir, acyclovir, or any component of the formulation.

 

 Route/Dosage

Herpes Zoster

Adults: PO 1 g tid for 7 days (initiate therapy within 48 hr of onset of rash).

Genital Herpes

Adults: PO Initial episodes: 1 g bid for 10 days (initiate therapy within 48 to 72 hr of onset of signs and symptoms). Recurrent episodes: 500 mg bid for 3 days (initiate therapy within 24 hr of onset of signs or symptoms). Suppressive therapy: 1 g once daily. If history of recurrence up to 9 recurrences/yr, 500 mg/day may be administered.

Herpes Labialis

Adults: PO 2 g bid for 1 day approximately 12 hr apart, initiated at earliest symptoms of cold sore (eg, tingling, burning, itching).

 

 Interactions

Cimetidine, probenecid:

Increased acyclovir serum concentrations.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

CNS: Headache; dizziness. GI: Nausea; vomiting; diarrhea; constipation; abdominal pain; anorexia. OTHER: Asthenia.

 

 Precautions

Pregnancy: Category B. Lactation: Undetermined (acyclovir is excreted in breast milk). CHILDREN: Safety and efficacy not established. Elderly: Dosage reduction may be necessary, depending on underlying renal status. Renal function impairment: Dosage reduction may be necessary; exercise caution when giving valacyclovir to patients with renal impairment or those receiving potentially nephrotoxic drugs. Immunocompromised: Valacyclovir is not indicated for use in immunocompromised patients.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • May be taken without regard to meals.
  • Store at room temperature.

 

 Assessment/Interventions

  • Obtain patient history.
  • Assess for history of present herpes zoster illness and time of rash onset. Start treatment up to 72 hr after rash onset.
  • Monitor for effectiveness of treatment: Crusting and disappearance of hepatic zoster lesions; pain relief.
  • Assess for history of present genital herpes illness and time of onset of signs and symptoms. Initiate treatment within 48 to 72 hr of onset of signs and symptoms.
  • Monitor for effectiveness of treatment (ie, improvement in signs and symptoms).
  • Assess for history of present, recurrent genital herpes illness and time of onset of signs and symptoms. Initate treatment within 24 hr of onset of signs and symptoms.
  • Monitor for effectiveness of treatment (ie, improvement in signs and symptoms).
OVERDOSAGE: SIGNS & SYMPTOMS
  Acute renal failure, anuria

 

 Patient/Family Education

Herpes Zoster

  • Advise patient to initiate treatment as soon as possible after diagnosis of herpes zoster and up to 72 hr after onset of zoster rash.
  • Instruct patient to take medication exactly as prescribed.
  • Instruct patient not to alter dose or discontinue medication without consulting health care provider.
  • Instruct patient not to take any other medications, including OTC medications, without checking with health care provider first.
  • Instruct patient to notify health care provider if there is no reduction in severity of lesions within 7 days.
  • Inform patient to report any serious side effects to health care provider, including: syncope, dizziness, nausea, vomiting, diarrhea, headache, abdominal pain, anorexia.

Genital Herpes

  • Advise patient to avoid sexual intercourse while genital herpes lesions are present.
  • Tell patient that valacyclovir is a treatment not a cure.
  • Advise patient to initiate therapy at first sign of symptoms of an episode.
  • Instruct patient to notify health care provider if there is no reduction in severity of signs and symptoms.

Drug Side Effects ::

(val-lay-SIGH-kloe-vihr HIGH-droe-KLOR-ide)
Valtrex
Tablets: 500 mg
Tablets: 1 g
Class: Anti-infective, Antiviral

 

 Action Converted to acyclovir, which then inhibits viral DNA replication by interfering with viral DNA polymerase.

 

 Indications Treatment of herpes zoster (shingles); treatment or suppression of genital herpes; treatment of herpes labialis (cold sores).

 

 Contraindications Hypersensitivity or intolerance to valacyclovir, acyclovir, or any component of the formulation.

 

 Route/Dosage

Herpes Zoster

Adults: PO 1 g tid for 7 days (initiate therapy within 48 hr of onset of rash).

Genital Herpes

Adults: PO Initial episodes: 1 g bid for 10 days (initiate therapy within 48 to 72 hr of onset of signs and symptoms). Recurrent episodes: 500 mg bid for 3 days (initiate therapy within 24 hr of onset of signs or symptoms). Suppressive therapy: 1 g once daily. If history of recurrence up to 9 recurrences/yr, 500 mg/day may be administered.

Herpes Labialis

Adults: PO 2 g bid for 1 day approximately 12 hr apart, initiated at earliest symptoms of cold sore (eg, tingling, burning, itching).

 

 Interactions

Cimetidine, probenecid:

Increased acyclovir serum concentrations.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

CNS: Headache; dizziness. GI: Nausea; vomiting; diarrhea; constipation; abdominal pain; anorexia. OTHER: Asthenia.

 

 Precautions

Pregnancy: Category B. Lactation: Undetermined (acyclovir is excreted in breast milk). CHILDREN: Safety and efficacy not established. Elderly: Dosage reduction may be necessary, depending on underlying renal status. Renal function impairment: Dosage reduction may be necessary; exercise caution when giving valacyclovir to patients with renal impairment or those receiving potentially nephrotoxic drugs. Immunocompromised: Valacyclovir is not indicated for use in immunocompromised patients.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • May be taken without regard to meals.
  • Store at room temperature.

 

 Assessment/Interventions

  • Obtain patient history.
  • Assess for history of present herpes zoster illness and time of rash onset. Start treatment up to 72 hr after rash onset.
  • Monitor for effectiveness of treatment: Crusting and disappearance of hepatic zoster lesions; pain relief.
  • Assess for history of present genital herpes illness and time of onset of signs and symptoms. Initiate treatment within 48 to 72 hr of onset of signs and symptoms.
  • Monitor for effectiveness of treatment (ie, improvement in signs and symptoms).
  • Assess for history of present, recurrent genital herpes illness and time of onset of signs and symptoms. Initate treatment within 24 hr of onset of signs and symptoms.
  • Monitor for effectiveness of treatment (ie, improvement in signs and symptoms).
OVERDOSAGE: SIGNS & SYMPTOMS
  Acute renal failure, anuria

 

 Patient/Family Education

Herpes Zoster

  • Advise patient to initiate treatment as soon as possible after diagnosis of herpes zoster and up to 72 hr after onset of zoster rash.
  • Instruct patient to take medication exactly as prescribed.
  • Instruct patient not to alter dose or discontinue medication without consulting health care provider.
  • Instruct patient not to take any other medications, including OTC medications, without checking with health care provider first.
  • Instruct patient to notify health care provider if there is no reduction in severity of lesions within 7 days.
  • Inform patient to report any serious side effects to health care provider, including: syncope, dizziness, nausea, vomiting, diarrhea, headache, abdominal pain, anorexia.

Genital Herpes

  • Advise patient to avoid sexual intercourse while genital herpes lesions are present.
  • Tell patient that valacyclovir is a treatment not a cure.
  • Advise patient to initiate therapy at first sign of symptoms of an episode.
  • Instruct patient to notify health care provider if there is no reduction in severity of signs and symptoms.

Drug Mode of Action ::  

(val-lay-SIGH-kloe-vihr HIGH-droe-KLOR-ide)
Valtrex
Tablets: 500 mg
Tablets: 1 g
Class: Anti-infective, Antiviral

 

 Action Converted to acyclovir, which then inhibits viral DNA replication by interfering with viral DNA polymerase.

 

 Indications Treatment of herpes zoster (shingles); treatment or suppression of genital herpes; treatment of herpes labialis (cold sores).

 

 Contraindications Hypersensitivity or intolerance to valacyclovir, acyclovir, or any component of the formulation.

 

 Route/Dosage

Herpes Zoster

Adults: PO 1 g tid for 7 days (initiate therapy within 48 hr of onset of rash).

Genital Herpes

Adults: PO Initial episodes: 1 g bid for 10 days (initiate therapy within 48 to 72 hr of onset of signs and symptoms). Recurrent episodes: 500 mg bid for 3 days (initiate therapy within 24 hr of onset of signs or symptoms). Suppressive therapy: 1 g once daily. If history of recurrence up to 9 recurrences/yr, 500 mg/day may be administered.

Herpes Labialis

Adults: PO 2 g bid for 1 day approximately 12 hr apart, initiated at earliest symptoms of cold sore (eg, tingling, burning, itching).

 

 Interactions

Cimetidine, probenecid:

Increased acyclovir serum concentrations.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

CNS: Headache; dizziness. GI: Nausea; vomiting; diarrhea; constipation; abdominal pain; anorexia. OTHER: Asthenia.

 

 Precautions

Pregnancy: Category B. Lactation: Undetermined (acyclovir is excreted in breast milk). CHILDREN: Safety and efficacy not established. Elderly: Dosage reduction may be necessary, depending on underlying renal status. Renal function impairment: Dosage reduction may be necessary; exercise caution when giving valacyclovir to patients with renal impairment or those receiving potentially nephrotoxic drugs. Immunocompromised: Valacyclovir is not indicated for use in immunocompromised patients.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • May be taken without regard to meals.
  • Store at room temperature.

 

 Assessment/Interventions

  • Obtain patient history.
  • Assess for history of present herpes zoster illness and time of rash onset. Start treatment up to 72 hr after rash onset.
  • Monitor for effectiveness of treatment: Crusting and disappearance of hepatic zoster lesions; pain relief.
  • Assess for history of present genital herpes illness and time of onset of signs and symptoms. Initiate treatment within 48 to 72 hr of onset of signs and symptoms.
  • Monitor for effectiveness of treatment (ie, improvement in signs and symptoms).
  • Assess for history of present, recurrent genital herpes illness and time of onset of signs and symptoms. Initate treatment within 24 hr of onset of signs and symptoms.
  • Monitor for effectiveness of treatment (ie, improvement in signs and symptoms).
OVERDOSAGE: SIGNS & SYMPTOMS
  Acute renal failure, anuria

 

 Patient/Family Education

Herpes Zoster

  • Advise patient to initiate treatment as soon as possible after diagnosis of herpes zoster and up to 72 hr after onset of zoster rash.
  • Instruct patient to take medication exactly as prescribed.
  • Instruct patient not to alter dose or discontinue medication without consulting health care provider.
  • Instruct patient not to take any other medications, including OTC medications, without checking with health care provider first.
  • Instruct patient to notify health care provider if there is no reduction in severity of lesions within 7 days.
  • Inform patient to report any serious side effects to health care provider, including: syncope, dizziness, nausea, vomiting, diarrhea, headache, abdominal pain, anorexia.

Genital Herpes

  • Advise patient to avoid sexual intercourse while genital herpes lesions are present.
  • Tell patient that valacyclovir is a treatment not a cure.
  • Advise patient to initiate therapy at first sign of symptoms of an episode.
  • Instruct patient to notify health care provider if there is no reduction in severity of signs and symptoms.

Drug Interactions ::

(val-lay-SIGH-kloe-vihr HIGH-droe-KLOR-ide)
Valtrex
Tablets: 500 mg
Tablets: 1 g
Class: Anti-infective, Antiviral

 

 Action Converted to acyclovir, which then inhibits viral DNA replication by interfering with viral DNA polymerase.

 

 Indications Treatment of herpes zoster (shingles); treatment or suppression of genital herpes; treatment of herpes labialis (cold sores).

 

 Contraindications Hypersensitivity or intolerance to valacyclovir, acyclovir, or any component of the formulation.

 

 Route/Dosage

Herpes Zoster

Adults: PO 1 g tid for 7 days (initiate therapy within 48 hr of onset of rash).

Genital Herpes

Adults: PO Initial episodes: 1 g bid for 10 days (initiate therapy within 48 to 72 hr of onset of signs and symptoms). Recurrent episodes: 500 mg bid for 3 days (initiate therapy within 24 hr of onset of signs or symptoms). Suppressive therapy: 1 g once daily. If history of recurrence up to 9 recurrences/yr, 500 mg/day may be administered.

Herpes Labialis

Adults: PO 2 g bid for 1 day approximately 12 hr apart, initiated at earliest symptoms of cold sore (eg, tingling, burning, itching).

 

 Interactions

Cimetidine, probenecid:

Increased acyclovir serum concentrations.

 

Drug Assesment ::

(val-lay-SIGH-kloe-vihr HIGH-droe-KLOR-ide)
Valtrex
Tablets: 500 mg
Tablets: 1 g
Class: Anti-infective, Antiviral

 

 Action Converted to acyclovir, which then inhibits viral DNA replication by interfering with viral DNA polymerase.

 

 Indications Treatment of herpes zoster (shingles); treatment or suppression of genital herpes; treatment of herpes labialis (cold sores).

 

 Contraindications Hypersensitivity or intolerance to valacyclovir, acyclovir, or any component of the formulation.

 

 Route/Dosage

Herpes Zoster

Adults: PO 1 g tid for 7 days (initiate therapy within 48 hr of onset of rash).

Genital Herpes

Adults: PO Initial episodes: 1 g bid for 10 days (initiate therapy within 48 to 72 hr of onset of signs and symptoms). Recurrent episodes: 500 mg bid for 3 days (initiate therapy within 24 hr of onset of signs or symptoms). Suppressive therapy: 1 g once daily. If history of recurrence up to 9 recurrences/yr, 500 mg/day may be administered.

Herpes Labialis

Adults: PO 2 g bid for 1 day approximately 12 hr apart, initiated at earliest symptoms of cold sore (eg, tingling, burning, itching).

 

 Interactions

Cimetidine, probenecid:

Increased acyclovir serum concentrations.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

CNS: Headache; dizziness. GI: Nausea; vomiting; diarrhea; constipation; abdominal pain; anorexia. OTHER: Asthenia.

 

 Precautions

Pregnancy: Category B. Lactation: Undetermined (acyclovir is excreted in breast milk). CHILDREN: Safety and efficacy not established. Elderly: Dosage reduction may be necessary, depending on underlying renal status. Renal function impairment: Dosage reduction may be necessary; exercise caution when giving valacyclovir to patients with renal impairment or those receiving potentially nephrotoxic drugs. Immunocompromised: Valacyclovir is not indicated for use in immunocompromised patients.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • May be taken without regard to meals.
  • Store at room temperature.

 

 Assessment/Interventions

  • Obtain patient history.
  • Assess for history of present herpes zoster illness and time of rash onset. Start treatment up to 72 hr after rash onset.
  • Monitor for effectiveness of treatment: Crusting and disappearance of hepatic zoster lesions; pain relief.
  • Assess for history of present genital herpes illness and time of onset of signs and symptoms. Initiate treatment within 48 to 72 hr of onset of signs and symptoms.
  • Monitor for effectiveness of treatment (ie, improvement in signs and symptoms).
  • Assess for history of present, recurrent genital herpes illness and time of onset of signs and symptoms. Initate treatment within 24 hr of onset of signs and symptoms.
  • Monitor for effectiveness of treatment (ie, improvement in signs and symptoms).
OVERDOSAGE: SIGNS & SYMPTOMS
  Acute renal failure, anuria

 

 Patient/Family Education

Herpes Zoster

  • Advise patient to initiate treatment as soon as possible after diagnosis of herpes zoster and up to 72 hr after onset of zoster rash.
  • Instruct patient to take medication exactly as prescribed.
  • Instruct patient not to alter dose or discontinue medication without consulting health care provider.
  • Instruct patient not to take any other medications, including OTC medications, without checking with health care provider first.
  • Instruct patient to notify health care provider if there is no reduction in severity of lesions within 7 days.
  • Inform patient to report any serious side effects to health care provider, including: syncope, dizziness, nausea, vomiting, diarrhea, headache, abdominal pain, anorexia.

Genital Herpes

  • Advise patient to avoid sexual intercourse while genital herpes lesions are present.
  • Tell patient that valacyclovir is a treatment not a cure.
  • Advise patient to initiate therapy at first sign of symptoms of an episode.
  • Instruct patient to notify health care provider if there is no reduction in severity of signs and symptoms.

Drug Storage/Management ::

(val-lay-SIGH-kloe-vihr HIGH-droe-KLOR-ide)
Valtrex
Tablets: 500 mg
Tablets: 1 g
Class: Anti-infective, Antiviral

 

 Action Converted to acyclovir, which then inhibits viral DNA replication by interfering with viral DNA polymerase.

 

 Indications Treatment of herpes zoster (shingles); treatment or suppression of genital herpes; treatment of herpes labialis (cold sores).

 

 Contraindications Hypersensitivity or intolerance to valacyclovir, acyclovir, or any component of the formulation.

 

 Route/Dosage

Herpes Zoster

Adults: PO 1 g tid for 7 days (initiate therapy within 48 hr of onset of rash).

Genital Herpes

Adults: PO Initial episodes: 1 g bid for 10 days (initiate therapy within 48 to 72 hr of onset of signs and symptoms). Recurrent episodes: 500 mg bid for 3 days (initiate therapy within 24 hr of onset of signs or symptoms). Suppressive therapy: 1 g once daily. If history of recurrence up to 9 recurrences/yr, 500 mg/day may be administered.

Herpes Labialis

Adults: PO 2 g bid for 1 day approximately 12 hr apart, initiated at earliest symptoms of cold sore (eg, tingling, burning, itching).

 

 Interactions

Cimetidine, probenecid:

Increased acyclovir serum concentrations.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

CNS: Headache; dizziness. GI: Nausea; vomiting; diarrhea; constipation; abdominal pain; anorexia. OTHER: Asthenia.

 

 Precautions

Pregnancy: Category B. Lactation: Undetermined (acyclovir is excreted in breast milk). CHILDREN: Safety and efficacy not established. Elderly: Dosage reduction may be necessary, depending on underlying renal status. Renal function impairment: Dosage reduction may be necessary; exercise caution when giving valacyclovir to patients with renal impairment or those receiving potentially nephrotoxic drugs. Immunocompromised: Valacyclovir is not indicated for use in immunocompromised patients.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • May be taken without regard to meals.
  • Store at room temperature.

 

 Assessment/Interventions

  • Obtain patient history.
  • Assess for history of present herpes zoster illness and time of rash onset. Start treatment up to 72 hr after rash onset.
  • Monitor for effectiveness of treatment: Crusting and disappearance of hepatic zoster lesions; pain relief.
  • Assess for history of present genital herpes illness and time of onset of signs and symptoms. Initiate treatment within 48 to 72 hr of onset of signs and symptoms.
  • Monitor for effectiveness of treatment (ie, improvement in signs and symptoms).
  • Assess for history of present, recurrent genital herpes illness and time of onset of signs and symptoms. Initate treatment within 24 hr of onset of signs and symptoms.
  • Monitor for effectiveness of treatment (ie, improvement in signs and symptoms).
OVERDOSAGE: SIGNS & SYMPTOMS
  Acute renal failure, anuria

 

 Patient/Family Education

Herpes Zoster

  • Advise patient to initiate treatment as soon as possible after diagnosis of herpes zoster and up to 72 hr after onset of zoster rash.
  • Instruct patient to take medication exactly as prescribed.
  • Instruct patient not to alter dose or discontinue medication without consulting health care provider.
  • Instruct patient not to take any other medications, including OTC medications, without checking with health care provider first.
  • Instruct patient to notify health care provider if there is no reduction in severity of lesions within 7 days.
  • Inform patient to report any serious side effects to health care provider, including: syncope, dizziness, nausea, vomiting, diarrhea, headache, abdominal pain, anorexia.

Genital Herpes

  • Advise patient to avoid sexual intercourse while genital herpes lesions are present.
  • Tell patient that valacyclovir is a treatment not a cure.
  • Advise patient to initiate therapy at first sign of symptoms of an episode.
  • Instruct patient to notify health care provider if there is no reduction in severity of signs and symptoms.

Drug Notes ::

(val-lay-SIGH-kloe-vihr HIGH-droe-KLOR-ide)
Valtrex
Tablets: 500 mg
Tablets: 1 g
Class: Anti-infective, Antiviral

 

 Action Converted to acyclovir, which then inhibits viral DNA replication by interfering with viral DNA polymerase.

 

 Indications Treatment of herpes zoster (shingles); treatment or suppression of genital herpes; treatment of herpes labialis (cold sores).

 

 Contraindications Hypersensitivity or intolerance to valacyclovir, acyclovir, or any component of the formulation.

 

 Route/Dosage

Herpes Zoster

Adults: PO 1 g tid for 7 days (initiate therapy within 48 hr of onset of rash).

Genital Herpes

Adults: PO Initial episodes: 1 g bid for 10 days (initiate therapy within 48 to 72 hr of onset of signs and symptoms). Recurrent episodes: 500 mg bid for 3 days (initiate therapy within 24 hr of onset of signs or symptoms). Suppressive therapy: 1 g once daily. If history of recurrence up to 9 recurrences/yr, 500 mg/day may be administered.

Herpes Labialis

Adults: PO 2 g bid for 1 day approximately 12 hr apart, initiated at earliest symptoms of cold sore (eg, tingling, burning, itching).

 

 Interactions

Cimetidine, probenecid:

Increased acyclovir serum concentrations.

 

 Lab Test Interferences None well documented.

 

 Adverse Reactions

CNS: Headache; dizziness. GI: Nausea; vomiting; diarrhea; constipation; abdominal pain; anorexia. OTHER: Asthenia.

 

 Precautions

Pregnancy: Category B. Lactation: Undetermined (acyclovir is excreted in breast milk). CHILDREN: Safety and efficacy not established. Elderly: Dosage reduction may be necessary, depending on underlying renal status. Renal function impairment: Dosage reduction may be necessary; exercise caution when giving valacyclovir to patients with renal impairment or those receiving potentially nephrotoxic drugs. Immunocompromised: Valacyclovir is not indicated for use in immunocompromised patients.

PATIENT CARE CONSIDERATIONS


 

 Administration/Storage

  • May be taken without regard to meals.
  • Store at room temperature.

 

 Assessment/Interventions

  • Obtain patient history.
  • Assess for history of present herpes zoster illness and time of rash onset. Start treatment up to 72 hr after rash onset.
  • Monitor for effectiveness of treatment: Crusting and disappearance of hepatic zoster lesions; pain relief.
  • Assess for history of present genital herpes illness and time of onset of signs and symptoms. Initiate treatment within 48 to 72 hr of onset of signs and symptoms.
  • Monitor for effectiveness of treatment (ie, improvement in signs and symptoms).
  • Assess for history of present, recurrent genital herpes illness and time of onset of signs and symptoms. Initate treatment within 24 hr of onset of signs and symptoms.
  • Monitor for effectiveness of treatment (ie, improvement in signs and symptoms).
OVERDOSAGE: SIGNS & SYMPTOMS
  Acute renal failure, anuria

 

 Patient/Family Education

Herpes Zoster

  • Advise patient to initiate treatment as soon as possible after diagnosis of herpes zoster and up to 72 hr after onset of zoster rash.
  • Instruct patient to take medication exactly as prescribed.
  • Instruct patient not to alter dose or discontinue medication without consulting health care provider.
  • Instruct patient not to take any other medications, including OTC medications, without checking with health care provider first.
  • Instruct patient to notify health care provider if there is no reduction in severity of lesions within 7 days.
  • Inform patient to report any serious side effects to health care provider, including: syncope, dizziness, nausea, vomiting, diarrhea, headache, abdominal pain, anorexia.

Genital Herpes

  • Advise patient to avoid sexual intercourse while genital herpes lesions are present.
  • Tell patient that valacyclovir is a treatment not a cure.
  • Advise patient to initiate therapy at first sign of symptoms of an episode.
  • Instruct patient to notify health care provider if there is no reduction in severity of signs and symptoms.

Disclaimer ::

The Information available on this site is for only Informational Purpose , before any use of this information please consult your Doctor .Price of the drugs indicated above may not match to real price due to many possible reasons may , including local taxes etc.. These are only approximate indicative prices of the drug.

DOWNLOAD OUR ANDROID APP

One of the 1st in India.High Quality Generic Medicine Portal Android Application for Online Oreder & Information.

For More Join Our Membership and Get Additional 25% off on Meds, also get MLM Benefits to get a permanent earning source.

Join Membership How to Search Medicine
Android App

We would like to keep you updated with special notifications.